drugset / Trial / NCT04696822

Bioavailability of Nasal Epinephrine

NCT04696822

Phase 1 Completed 12 enrolled Nasus Pharma
NaSequentialOpen-labelTreatment

Summary

A Study to Compare the Bioavailability of Epinephrine following a Single Nasal Dose of FMXIN002 Microspheres Powder with Epinephrine 0.3 mg Intramuscular Injection in Adult Subjects with Seasonal Allergic Rhinitis with and without Nasal Allergen Challenge

Timeline

Start
2020-11-01
Primary completion
2021-09-28
Completion
2021-09-28

Drugs

EvaluationDrugModalityDoseRoute
Subject Epinephrine Other / unclassified 0.3 mg Intranasal
Subject Epinephrine Other / unclassified 1.6 mg Intranasal
Subject Epinephrine Other / unclassified 3.2 mg Intranasal

Indications